GSK targets a new indication for Nucala, flags PhIII success for a rare disease
GlaxoSmithKline may soon have a new market for its asthma drug Nucala (mepolizumab). The pharma giant says that their Phase III study of the drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
